Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

EYE on CHINA
Partner State Key Laboratory of Pharmaceutical Biotechnology opened at HKU
The Ministry of Science and Technology of the Central Government has approved the application from Li Ka Shing Faculty of Medicine, the University of Hong Kong in July to establish a “Partner State Key Laboratory of Pharmaceutical Biotechnology” at HKU, in strategic collaboration with State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University. The Laboratory aims to conduct basic, clinical and translational research on obesity, diabetes and its cardiovascular complications. This State Key Laboratory is the fifth one set up at HKU which will continue its contribution to the Mainland and local scholarly and research exchanges.

Professor Xu Aimin, Professor of Department of Medicine, Li Ka Shing Faculty of Medicine, HKU is the director of the Laboratory. He says, “ Up to date, about 93 million adults are now suffering from diabetes and over 140 million adults with prediabetes are at high risk to develop overt diabetes in China. Diabetes is not only a major risk factor for cardiovascular disease, but is also causally associated with many types of cancers. These chronic diseases hence impose an enormous medical and economic burden to our society. Development of key research platforms and innovative medicine for diabetes and related chronic diseases are a major strategic emphasis in the national 12th five-year plan of China. The establishment of the Laboratory is believed to foster and bring pivotal result of the researches.”

“The Partner State Key Laboratory of Pharmaceutical Biotechnology”, located at Li Ka Shing Faculty of Medicine, HKU, is run by the Department of Medicine and Department of Pharmacology and Pharmacy. The team of HKU has nearly 80 researchers. The Chinese University of Hong Kong and The Hong Kong University of Science and Technology have formed an interdisciplinary team to participate in the research.

The research team hopes that the establishment of this laboratory will serve as a key platform to strengthen the collaborations and academic exchange with the Mainland and international scientists, and to train young researchers, and to support the pharmaceutical industries as well as clinical practice in Hong Kong and Mainland China.

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.